Pharma exports slowest in 15 yrs, to miss target this fiscal

India's pharmaceutical exports registered slowest growth in at least 15 years at 1.2 per cent to $14.84 billion last fiscal amid growing tension with the US over intellectual property rights related issues.

As the IPR issues raised by the US - India's biggest market - are unlikely to be resolved anytime soon, industry observers say that pharma exports will miss the target of $25 billion set for 2014-15 in a government strategy paper.

According to the Commerce Ministry data, in 2012-13, the country's pharma exports aggregated $14.66 billion.

The growth registered in 2013-14 is the slowest in nearly 15 years. The previous slowest was in 2009-10 when the pharma exports grew by just 5.9 per cent. In calendar year 2000, they grew by 7 per cent.

"2013-14 has seen slowdown in growth because of the US raising concerns and due to increase in global competition," PV Appaji, Executive Director, Pharmexcil told PTI.

Elaborating on hurdles faced by Indian companies, an official said: "The US industry is alleging that India's IPR laws particularly with regard to pharma sector discriminate American firms. They are putting pressure on their government to take actions against India."

The US is the top destination for Indian pharma exports followed by the UK. America accounts for about 25 per cent of India's pharma exports.

The Obama administration has been strongly criticising India's investment climate and IPR laws, especially in the pharmaceuticals sectors.

US pharma companies had objected to India's move to issue a compulsory license in March, 2012 to Hyderabad-based Natco Pharma to manufacture and sell Bayer's cancer-treatment drug 'Nexavar' at a cheaper price.

Compounding the problems for Indian pharma firms, Vietnam too has raised concerns over medicines imported from India. An industry official stated that "if Vietnam were to ban imports from India, It will further impact our exports".

Appaji, however, said: "DCGI is looking into concerns raised by Vietnam over quality defects in drugs supplied from various countries, including India which is a major supplier to the country."

Despite the challenges, he said: "India has been able to make its name as a quality supplier of affordable medicines across the globe. We are expecting around 12 per cent growth this fiscal."

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • It will take at least 4 more quarters for corporate bottomlines to turn around

    Aggregate numbers from corporate results in the June quarter of 2014-15 are hardly different from the previous six quarters, with no positive surprise

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Tushar Gandhi

Dealing with a sin called insensitivity

Rage and the notion of being above the law — ...

Kuruvilla Pandikattu SJ

India’s greatest gift to the world

What we hear most often about India these days is ...

Gautam Gupta

Why must innerwear be our best kept secret?

While women’s outerwear rules the marketing roost in India, unfortunately, ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture